$42.340
+0.021 (+0.05%)At close
LIME News
LIME Events
Sees Q3 Adjusted EBITDA of $120M-$130M
Sees Q3 adjusted EBITDA $120M-$130M.
Lime Reports Q2 Revenue of $304.22M, Beating Expectations
Reports Q2 revenue $304.22M, consensus $282.54M. "We are pleased to report record revenue and strong bottom line performance for our first quarter as a public company. The results were fueled by our competitive advantages made possible by our vertically integrated platform, continued investments in both existing and new markets and our initiatives to drive rider engagement," said Wayne Ting, CEO. "Transportation is undergoing significant transformation, including the growth and adoption of micromobility, and Lime is the largest global shared micromobility business. We believe we're still in the early stages of capturing this significant opportunity, and the Lime team continues to execute on our mission to build a future where transportation is shared, affordable and carbon-free."
Sees FY26 Adjusted EBITDA of $265M-$285M
Sees FY26 adjusted EBITDA $265M-$285M. Sees FY26 capital expenditures of approximately $180M-$185M.
Scribe Therapeutics Debuts Above Issue Price on First Trading Day
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum behind its platform story.LATEST IPOS AND DIRECT LISTINGS:Scribe Therapeuticsopened on July 24 at $25. Scribe, which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into "purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases," starting with cardiometabolic disease.RECENT SPAC IPOS:Market Technology Acquisitionopened on July 24 at $10.00. The company's primary focus is businesses operating "across the global capital markets ecosystem, with particular emphasis on licensed U.S. equities and options clearing businesses and related market infrastructure, and post-trade, brokerage, custody, execution and financial technology platforms."B&R Technology Mergeropened on July 21 at $9.96. The company may pursue an initial business combination target in any business or industry. Citigroup is acting as sole bookrunner and representative of the underwriters.Southern Cross Acquisition Iopened on July 21 at $10. D. Boral Capital is acting as sole book-running manager of the offering.PERFORMANCE:Prices as of 11 am ET on Monday, July 27 -Scribe Therapeutics – down about 13% at $18.86.RECENT IPOS TO WATCH:Bending Spoons, Neutron Holdingsand ITG, Inc.are already seeing coverage roll out as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include EvoAir, Jersey Mike's Subs, Reformation, Braveheart Bio, and Inspire Brands.Clickto see upcoming IPO calendar on TipRanks.EvoAir Holdingshas filed for a firm commitment initial public offering of shares of common stock and anticipates that the initial public offering price of shares will be between $4.00 and $5.00 per share. The company said it will apply to list its common stock on the Nasdaq Capital Market under the symbol "EVOH". EvoAir Group is an emerging green technology focusing on eco-friendly heating, ventilation, air conditioning inventions and efforts in the environmental, social and governance initiatives. The Group is principally engaged in the research and development, manufacturing, sale and marketing of HVAC products for residential, commercial and industrial uses.Jersey Mike's Subsannounced that it has commenced a roadshow for its proposed initial public offering of 43,478,261 shares of its Class A common stock to be sold by Jersey Mike's and certain of its existing stockholders. The IPO price is currently expected to be between $21.00 and $25.00 per share. In addition, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 6,521,739 shares of the Company's Class A common stock to cover over-allotments at the IPO price, less underwriting discounts and commissions. Jersey Mike's expects to list its Class A common stock on the New York Stock Exchange under the ticker symbol "JMKE."Reformationannounced the launch of its roadshow for the initial public offering of 14,062,500 shares of its common stock. Reformation is offering 9,478,821 shares of common stock and certain of its existing stockholders are offering 4,583,679 shares of common stock. In connection with the offering, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 2,109,375 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $15.00 and $17.00 per share. Reformation has been approved to list its common stock on the New York Stock Exchange under the ticker symbol "REF."Braveheart Biohas filed with the SEC for an initial public offering of shares of its common stock and applied to list its common stock on The Nasdaq Global Market under the symbol "BRVE". Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are listed as the joint bookrunners. The prospectus states, "We are a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM."Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Bending Spoons IPO Priced at $29, Opens at $31
Several companies made their market debuts last week, with Bending Spoons, ITG and Neutron Holdings opening for trading across a mix of pricing levels.LATEST IPOS AND DIRECT LISTINGS:Bending Spoonsopened on July 1 at $31.00. The company priced its 57.97M share initial public offering at $29.00, above the $26.00-$28.00 range. Bending Spoons is a digital applications company whose portfolio includes note-taking app Evernote, video platform Vimeo, events marketplace Eventbrite and AOL.ITG, Inc.opened on July 1 at $18. The company priced 19.51M shares at $16.00, below the $19.00-$22.00 range. ITG is a provider of end-to-end services to the communications and digital infrastructure industries.Neutron Holdingsopened on July 1 at $27. The firm priced 6.96M shares at $25.00, in the middle of the deal range of $24.00-$26.00. Neutron Holdings, doing business as Lime, describes itself as "a leading global shared micromobility business" that partners with cities to deploy e-bikes and e-scooters to serve shorter distance trips.RECENT SPAC IPOS:Viking Acquisition Corp. IIopened on July 2 at $10.04. The blank check company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region.Osprey Acquisition IIIopened on July 1 at $10.03. The blank check company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution, but says its primary focus will be to "identify companies that are deploying disruptive technologies and next-generation infrastructure that modernize energy systems, enable AI-driven optimization, and support the resilient, sustainable backbone of global connectivity."PERFORMANCE:Prices as of 10:30 am ET on Monday, July 6 -Bending Spoons – down over 6% at $33.76;ITG, Inc. – down about 6% at $14.60;Neutron Holdings – fractionally down at $24.88.RECENT IPOS TO WATCH:SpaceX, Forbright, ERock, and WhiteHawk Mineralsare already seeing coverage roll out, while Avalanche Treasury Co.is among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Jersey Mike's Subs, Kardigan, Inspire Brands, and Tarsier Pharma.Clickto see upcoming IPO calendar on TipRanks.Jersey Mike's Subshas filed an initial public offering of shares of Class A common stock. The company has applied to list its shares of Class A common stock on the New York Stock Exchange under the trading symbol "JMKE." Morgan Stanley, Jefferies, and J.P. Morgan are acting as global coordinators and joint bookrunning managers for the offering. Barclays and Guggenheim Securities are acting as co-global coordinators and joint bookrunning managers. BofA Securities, Goldman Sachs, Evercore ISI, UBS Investment Bank, Baird, Wells Fargo Securities, William Blair, RBC Capital Markets, Deutsche Bank Securities, Wolfe Nomura Alliance, Piper Sandler, Raymond James, Stifel, TD Securities, BTIG, Mizuho, Societe Generale, and Truist Securities are acting as joint bookrunning managers. Blackstone Capital Markets, Loop Capital Markets, and Tigress Financial Partners are acting as co-managers.Kardiganhas filed an initial public offering of shares of its common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "KARD." JP Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as the underwriters for the offering.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial... Although we are still early in this journey, I believe we have the technology, the team, the discipline, and the persistence required to build an enduring company."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.





